|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cystic Fibrosis | |||||
| Pancreatic Insufficiency | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Exocrine Pancreatic Insufficiency | |||||
| Fibrosis | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Genetic Diseases, Inborn | |||||
| Infant, Newborn, Diseases | |||||
| Lung Diseases | |||||
| Pancreatic Diseases | |||||
| Pathologic Processes | |||||
| Respiratory Tract Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| PANCRECARB® (pancrelipase) | |||||
| Placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Pancrelipase | |||||
| 6 | More general drug interventions related to this trial | ||||
| Gastrointestinal Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Digestive Care, Inc. | |||||